Aquarius acquired by Matinas BioPharma after Matinas raised approximately $20M

Aquarius Biotechnologies participated in the tTAp partnering with three potential CEOs. In the tTAp process, they were advised to focus on their lead compounds, and subsequently received an NIH grant to more their lead compound forward. They worked with one of them to develop and improve their messaging and presentation. Aquarius BioPharma’s lead compounds are now Matinas BioParmas’ lead compounds. See Aquarius in action at the tTAp


Wellesley Pharmaceuticals ~ $1M Raise

At the tTAp Wellesley revised their message and strategy to reach investors. Strengthening the delivery of their clinical potential of their compound combination, Wellesley partnered with a number of catalysts who help them connect with potential partners in Europe and the US. See Wellesley in action at the tTAp



– Endomedix receives a $1.5 M NIH Grant
– Endomedix selected as NIH featured at Bio 2015

Endomedix partnered with a catalyst with extensive experience in the hemostatic sealant market place at the tTAp. See Endomedics in action at the tTAp



Raised $400,000 from a single investor
– LifeCuff as IRT Won NJTC Venture Fair Life Science Award

tTAp worked with IRT, or LifeCuff as it is now known, several times over the past year+. Refining their path and their needs, the tTAp advised LifeCuff on strategies to raise funds, and suggested potential avenues for growth. tTAp sponsored LifeCuff’s participation at the NJTC Venture Fair, and worked with them to prepare for the conference. See LifeCuff in action at the tTAp.



If you know of additional results, or are a tTAp company and would like to be considered for investor presentations, please contact us at